LA JOLLA, Calif.--(BUSINESS WIRE)--Fate Therapeutics, Inc. announced the continued expansion of its executive management team with the addition of Ken Batchelor, Ph.D., as the Company’s chief scientific officer. Dr. Batchelor brings more than 28 years of experience in drug discovery and development, serving most recently as senior vice president at GlaxoSmithKline. During his career, he has advanced 11 drug candidates from target identification to positive completion of Phase 2 clinical studies. Dr. Batchelor will lead the Company’s pursuit of discovering and developing small molecules and biologics to guide cell fate for therapeutic purposes.
